Astria Therapeutics, Inc. (ATXS) Stock Analysis & Investment Frameworks
Astria Therapeutics, Inc. (ATXS) stock analysis on Invetso. Review Astria Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Astria Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Astria Therapeutics, Inc. Key Financial Metrics
- Market Cap: $718.13M
- Revenue: $N/A
- ROE: -26.20%
- ROIC: -28.00%
- Dividend Yield: N/A
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.
Astria Therapeutics, Inc. Investment Frameworks
Invetso analyzes Astria Therapeutics, Inc. (ATXS) across the following frameworks:
- Astria Therapeutics, Inc. 10Y Growth Potential
- Astria Therapeutics, Inc. Scenario Analysis
- Astria Therapeutics, Inc. Risks & Opportunities
- Astria Therapeutics, Inc. Economic Moat
- Astria Therapeutics, Inc. Business Model
- Astria Therapeutics, Inc. Management
- Astria Therapeutics, Inc. SWOT Analysis
- Astria Therapeutics, Inc. Porter's 5 Forces
- Astria Therapeutics, Inc. PESTLE Analysis
- Astria Therapeutics, Inc. ESG Analysis